• Price (EUR)1.88
  • Today's Change-0.005 / -0.27%
  • Shares traded15.29k
  • 1 Year change31.47%
  • Beta0.3107
Data delayed at least 15 minutes, as of Oct 20 2017 16:36 BST.
More ▼

Profile data is unavailable for this security.

About the company

aap Implantate AG is a Germany-based provider of medical devices for human muscular and skeletal systems. The Company focuses on trauma and biomaterials products for orthopedics. The Biomaterials portfolio comprises bone substitutes for the filling of aseptic bone defects, bone cements and accessories for the application in arthroplasty, bone cements and accessories for the application in vertebroplasty and kyphoplasty. The trauma portfolio includes a wide range of cannulated screws, standard plates and screws for miniature, small and large bone fragments, among others . It also develops LOQTEQ, a technology that allows for fracture compression with subsequent locking fixation in one surgical step. The Company operates a network of distributors in more than 60 countries, and cooperates directly with physicians and hospital customers.

  • Revenue in EUR (TTM)9.98m
  • Net income in EUR-9.46m
  • Incorporated--
  • Employees143.00
  • Location
    Aap Implantate AGLorenzweg 5BERLIN 12099GermanyDEU
  • Phone+49 30750190
  • Fax+49 3 075019111
  • Websitehttp://www.aap.de/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Bio Gate AG3.54m-286.53k16.33m22.00--16.41--4.61-0.0526-0.05260.6510.18281.663.667.02---14.60-45.37-33.38-75.5974.9176.65-8.81-41.740.768-6.830.00--21.597.1596.75--34.39--
HumanOptics AG11.56m31.00k27.78m115.00896.317.0062.712.400.010.013.741.281.540.72465.67--0.41260.98280.59491.4487.3380.470.26810.67711.242.230.1962--7.889.40-80.25--50.07--
aap Implantate AG9.98m-9.46m53.85m143.00--1.15--5.40-0.3067-0.31090.32371.630.15550.11332.4464,387.10-14.73-6.81-16.21-8.2988.4276.59-94.75-20.735.19-30.960.0595---14.61-18.522.87------
Geratherm Medical AG21.15m2.11m63.48m205.0029.673.0120.393.000.43230.43234.344.270.77590.88665.79103,677.507.156.048.417.0467.1058.959.229.033.47--0.086191.44-0.83213.99-
MagForce AG565.03k-7.06m202.82m45.00--11.19--358.95-0.2756-0.27560.0220.68800.02219.292.8720,179.64-27.48-15.48-31.81-22.73-39.48-64.84-1,249.60-561.762.30-34.440.221---81.6110.03-367.51------
Pulsion Medical Systems SE31.67m5.41m206.25m68.0038.187.4430.326.510.65490.65493.843.360.97111.793.88465,727.1016.5831.1921.2451.7363.6663.7717.0741.451.7915.740.00107.76-5.19-5.73--------
Data as of Oct 20 2017. Currency figures normalised to Aap Implantate AG's reporting currency: Euro EUR
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.